Future Perspectives for Haploidentical SCT
Stem Cell Biology and Regenerative Medicine, Springer Nature, ss.189-199, 2017
- Yayın Türü: Kitapta Bölüm / Araştırma Kitabı
- Basım Tarihi: 2017
- Doi Numarası: 10.1007/978-3-319-65319-8_13
- Yayınevi: Springer Nature
- Sayfa Sayıları: ss.189-199
- Anahtar Kelimeler: Graft-versus-host Disease (GvHD), Haploidentical Donors, Haploidentical HSCT, Hematopoietic Stem Cell Transplantation (HSCT), Non-inherited Maternal Antigens (NIMA)
- Ankara Üniversitesi Adresli: Evet
Özet
Allogeneic hematopoietic stem cell transplantation (HSCT) remains as the sole curative option for many malignant and non-malignant hematological disorders. The selection of proper donor among the available candidates is a crucial step during the initial work-up. Despite promising results with haploidentical HSCT, there are still several unresolved issues. An area of active reasearch constitutes the selection of the most appropriate haploidentical donors via several predefined criteria including the presence of donor-specific HLA antibodies, donor-recipient HLA mismatch, non-inherited maternal antigens (NIMA) and natural killer cell (NK cell) alloreactivity. Ongoing efforts to optimize the procedure in order to enhance immune reconstitution and decrease complications, including graft versus host disease (GvHD), infections, graft failure and relapse have so far yielded promising results. The results of further research with higher quality features are expected to unveil a more extensive list of indications for haploidentical SCT in the near future.